# QIBA PET-Amyloid Biomarker Committee Friday, December 11, 2020 at 9 AM CT Call Summary

## In attendance:

Dawn Matthews, MS (Co-chair)Rachid Fahmi, MSc, PhDP. David MozlAnne Smith, PhD (Co-chair)Clara FerreiraNancy ObuchTammie Benzinger, MD, PhDNorman Foster, MDLindsay QuanOrest Boyko, MD, PhDAdriaan Lammertsma, PhDJean-Luc Vance

P. David Mozley, MD Nancy Obuchowski, PhD Lindsay Quandt, MS, MBA Jean-Luc Vanderheyden, PhD **RSNA** Joe Koudelik Julie Lisiecki

## Moderator: Ms. Matthews

## **DRO Progress:**

- After testing the DRO iteration, it was discovered that an incorrect aspect ratio was used; so, adjustments have been made by Dr. Pierce and Mr. Byrd
- DRO was expanded to include an MRI and noise-free PET images
- The BC now has a usable form for conformance testing
- Ms. Matthews suggested that she, Drs. Smith, Pierce, and Ms. Ferreira have a call offline soon to finalize DRO testing, as Ms. Ferreira volunteered to do testing with GE software
- Additional DRO testing will help to get the Profile closer to the Technically Confirmed Stage and provide closure for the BC

## Publishing the PET Amyloid Profile:

- The BC plans to draft a paper for peer-reviewed publication to better promote QIBA and use of the Profile
- Dr. Kinahan's <u>FDG-PET article</u> will be referenced for the QIBA Process and the article itself will serve as a template
  - The article included details about the QIBA Process, helpful tables, charts, and outlines
    - One of the most useful tables explains the statistics in an easy-to-understand manner for readers
    - The paper also outlines the structure of the Profile at-a-glance and provides examples of normative requirements, etc.
- Reviewing the BC's <u>2017 poster</u> could also be helpful, as the poster summarized main topics succinctly
- Collaborators on the paper were invited and the following volunteers have agreed:
  - Clara Ferreira (Section 5.4)
  - Norman L. Foster, MD (Section 2)
  - Dawn Matthews, MS
  - Nancy Obuchowski, PhD (Section 4)

- Anne Smith, PhD (scanner and recon details)
- Jean-Luc Vanderheyden, PhD (Section 5.1)
- RSNA Staff will follow up with volunteer authors with details
- Ms. Matthews to follow up with volunteer authors regarding their chosen sections
- Dr. Mozley offered some advice to writers suggesting the following:
  - $\circ$  It would be helpful to attribute any borrowed text to QIBA and the QIBA FDG-PET/CT BC
  - Volunteer authors are encouraged to draft text with initial ideas text, then polish their writing later
  - Dr. Mozley notes that timelines with realistic deadlines are critical to help maintain forward momentum
  - For a potential future Tau Profile, it may be possible to use "find" and "replace," using the PET Amyloid template as a starting point, with finer edits based on group discussion
    - If BC members are interested in joining a Tau BC, they are encouraged to email RSNA staff at <u>QIBA@rsna.org</u>.

## Next meeting topics:

- Discuss progress on writing assignments with the PET Amyloid Profile-related manuscript
- Set the stage for a Tau Profile

### **Action items**

- Dr. Fahmi and Ms. Ferreira to test the new DRO to make certain that the noise levels are correct
- Ms. Matthews to follow up with Dr. Pierce and Mr. Byrd
- Dr. Smith or Ms. Matthews to add a Profile note indicating that data are simulated to ensure that no questions are raised pertaining to HIPAA regulations
- Ms. Matthews to reformat the Profile checklist from Excel to Word for ease of use
- Team to start drafting Profile publication

#### **QIBA Nuclear Medicine Schedule:**

01/15	PET Amyloid BC @ 9 am CT
02/12	PET Amyloid BC @ 9 am CT
02/	NM Coordinating Ctte - TBD